Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-022 青岛蔚蓝生物股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次会议是否有否决议案：无 审议结果：通过 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 5 月 16 日 (二) 股东会召开的地点：青岛市崂山区九水东路 596-1 号 蔚蓝生物创新园 B 座 多媒体会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 份总数的比例（%） (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式召开。 现场会议由公司董事长陈刚先生主持。会议召集、召开和表决程序符合《公司法》 及《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 股东会。 二、 议案审议情况 (一) 非累积投票议案 表决情况： | | 同意 | | | 反对 | | 弃权 | | | | --- | --- | --- | ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-022 青岛蔚蓝生物股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 192 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 163,833,460 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 64.7489 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式召开。 (一) 股东会召开的时间：2025 年 5 月 16 日 (二) 股东会召开的地点：青岛市崂山区九水东路 596-1 号 蔚蓝生物创新园 B 座 多媒体会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 现场会议由公司董事长陈刚先生主持。会议召 ...

北京海润天睿律师事务所 二〇二五年五月 关于青岛蔚蓝生物股份有限公司 2024 年年度股东会的 法律意见书 中国·北京 地址：朝阳区建外大街甲 14 号广播大厦 5 层、9 层、10 层、13 层、17 层 邮编：100022 电话：（010）65219696 传真：（010）88381869 北京海润天睿律师事务所 关于青岛蔚蓝生物股份有限公司 2024 年年度股东会的法律意见书 致：青岛蔚蓝生物股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受青岛蔚蓝生物股份有限 公司（以下简称"公司"）的委托，指派本所律师出席公司 2024 年年度股东会， 并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司治理准则》 《公司章程》及其他相关法律、法规的规定，就公司本次股东会的召集、召开程 序、出席会议人员的资格、召集人资格、表决程序及表决结果等有关事宜出具本 法律意见书。 对本法律意见，本所律师声明如下： 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤 ...

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

Core Viewpoint - Synthetic biology concept stocks are experiencing significant upward movement, with notable gains in several companies [1] Group 1: Company Performance - Chuaning Biological (301301) reached a 20% daily limit increase [1] - Bawi Co., Ltd. saw an increase of over 20% [1] - Toxin Pharmaceutical (301089) rose by more than 10% [1] - Jindawei (002626), Oukang Pharmaceutical, and Weilan Biological (603739) also experienced upward trends [1] Group 2: Market Activity - There is a notable influx of dark pool funds into these stocks [1]

Group 1 - The sugar substitute concept declined by 0.82%, ranking among the top declines in the concept sector, with companies like Baolingbao, Bailong Chuangyuan, and Chenguang Biotech experiencing significant drops [1][2] - Among the sugar substitute stocks, 8 saw price increases, with Zhonghua International, Luxin Investment, and Xinghu Technology rising by 1.37%, 1.34%, and 1.09% respectively [1][2] - The sugar substitute sector experienced a net outflow of 118 million yuan, with 17 stocks seeing net outflows, and 5 stocks with outflows exceeding 10 million yuan, led by Jinhai Biological with a net outflow of 44.98 million yuan [2][3] Group 2 - The top net inflow stocks in the sugar substitute sector included Jinhai Industrial, Rhine Biological, and Shengquan Group, with net inflows of 16.36 million yuan, 12.29 million yuan, and 5.05 million yuan respectively [2][3] - The outflow leaderboard for the sugar substitute sector featured Jinhai Biological, Yasheng Group, and Baolingbao, with respective outflows of 44.98 million yuan, 25.20 million yuan, and 22.92 million yuan [2][3] - The trading activity in the sugar substitute sector showed varied turnover rates, with Baolingbao at 14.36% and Jinhai Biological at 6.48% [2][3]

Group 1 - The A-share biopharmaceutical sector experienced an initial surge, with Reap Bio rising over 8% [1] - ST Xianfeng increased by more than 3.5% [1] - Other companies such as Sinovac Biotech, Oriental Bio, KQ Biotech, and Blue Horizon Biotech also saw gains [1]

青岛蔚蓝生物股份有限公司 2024 年年度股东会 会议材料 二〇二五年五月十六日 | | | 青岛蔚蓝生物股份有限公司 2024 年年度股东会会议议程 一、会议召开的基本情况 （一）会议类型和届次：2024 年年度股东会 （二）会议召开时间、地点： 会议时间：2025 年 5 月 16 日 14 点 30 分 会议地点：青岛市崂山区九水东路 596-1 号蔚蓝生物创新园 B 座多媒体会 议室 为了维护青岛蔚蓝生物股份有限公司（以下简称"公司"）全体股东的合法 权益，确保股东会的正常秩序和议事效率，保证大会的顺利进行，根据中国证监 会《上市公司股东会规则》规定和《公司章程》《股东会议事规则》等相关法律 法规的规定，特制定本次股东会须知如下： （三）会议出席人员 二、会议议程 （五）与会代表休息（工作人员统计现场投票结果），等待接收网络投票结 果； （六）网络投票结果产生后，宣读投票结果和决议； （七）律师宣读本次股东会法律意见书，与会董事等人员在会议决议及记录 上签字； （八）宣布会议结束。 1、股东、股东代表 2、公司董事、监事和高级管理人员 3、公司聘请的律师 4、其他人员 （一）报告会议出席情况，宣布会议 ...

Core Insights - In 2024, the company achieved operating revenue of 1.32 billion yuan, a year-on-year increase of 10.16%, while net profit attributable to shareholders was 63 million yuan, a decline of 22.39% [1] - The decline in profit is attributed to increased depreciation expenses after the completion of the animal health industrial park, a 17.49% rise in management expenses, and a 46.48% increase in financial expenses due to interest expenses being recognized as costs [1] Enzyme Business - The enzyme business generated revenue of 505 million yuan in 2024, a year-on-year growth of 14.34%, becoming the main driver of the company's revenue growth [2] - The gross profit margin reached 63.69%, an increase of 2.89 percentage points, driven by continuous investment in technological innovation and optimization of production processes [2] - The company is expanding into various fields including industrial enzymes, food enzymes, and pharmaceutical enzymes, and has established an AI technology development laboratory to enhance R&D efficiency [2] Animal Health Products - Revenue from the animal health products business was 308 million yuan in 2024, a slight increase of 3.56%, but the gross profit margin fell to 33.51%, down 8.23 percentage points [3] - The decline in gross profit margin is primarily due to increased depreciation after the industrial park's completion, but long-term benefits are expected from improved product structure and quality [3] - The company plans to focus on biological products, particularly pig vaccines and imported generics, while also expanding into the pet medicine sector [3] Capacity and R&D Investment - With the increase in new capacity utilization and the gradual release of new products, the profitability of the animal health business is expected to recover [4] - The company invested 118 million yuan in R&D in 2024, a year-on-year increase of 6.81%, accounting for 8.95% of revenue, with 266 R&D personnel [4] - The company has established six technology centers and two key laboratories, with major projects expected to be operational by 2025, laying a foundation for future growth [4] Profit Forecast and Investment Recommendation - The expected EPS for 2025-2027 is projected to be 0.44 yuan, 0.51 yuan, and 0.60 yuan, corresponding to dynamic PE ratios of 29, 24, and 21 times, respectively, maintaining a "hold" rating [4]